North American Pulmonary drug delivery devices Market Research Report
- Report Code: RE 1001
- Publish Date: Upcoming
The North American pulmonary drug delivery devices market is mainly driven by patent cliffs, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies on in-house capabilities-for the development of oral drug delivery technologies. It was valued at $13.80 billion in 2013, and expected to grow at a CAGR of 11.80% to reach $24.00 billion by 2018.
The report ‘North American Pulmonary Drug Delivery devices Market forecast, 2012-2018’ analyzes the market by three segments, namely nebulizers, dry powder inhalers (DPIs), and metered dose inhalers (MDIs).
A significant trend in the usage of pulmonary devices is a shift from the traditionally used nebulizers to pressurized MDIs (pMDIs), and in the recent years, from pMDIs to DPIs. While pMDIs currently retain their position with the largest market size, DPIs are expected to overtake the market share of pMDIs. The market has also become more patient-centric with patient-friendly features such as dose counters and devices requiring low inspiratory efforts. Application of pulmonary delivery for non-respiratory therapies is expected to be a huge opportunity in this market.
The North American market segmentation in this report comprises of the United States and Canada. The key drivers for the pulmonary drug delivery market in North America are the robust pharmaceutical industry, large number of pharmaceutical companies and drug delivery technology providers, and the increasing number of collaborations and partnerships between technology providers and pharmaceutical companies. In addition, an increased demand for self-administration & home healthcare devices and increasing applications of inhalers, transdermal patches, and transmucosal systems for chronic disease areas such as migraine, diabetes, cancer pain, and asthma have boosted the growth of this market.
The report also provides an extensive competitive landscaping of companies operating in the pulmonary drug delivery devices market. The main companies operating in the market are GlaxoSmithKline Pharmaceuticals Limited (GSK), Boehringer Ingelheim GmbH, and Astra Zeneca.
Segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options
Along with the market data, you can also customize the MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep-dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix which gives a detailed comparison of the product portfolio of each company, mapped at country and sub-segment level
- End-user Adoption rate analysis of the products (segment-wise and country-wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
Pharmacists Forum
- Fast turn-around analysis of pharmacists’ response to market events and trends
- Pharmacists’ opinion about pulmonary drug delivery devices products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our in-built social connect tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
North American Drug Delivery Devices Market The North American Drug Delivery Devices Market was valued at $16 billion in 2013 and expected to be $110 billion by 2018, growing at a CAGR of 8.9%. The report “North American Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.). |
Upcoming |
|
|
European Drug Delivery Devices Market The European Drug Delivery Devices Market was valued at $45 billion in 2013 and expected to be $63 billion by 2018, growing at a CAGR of 8.3%. The report “European Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.). |
Upcoming |
|
|
Asian Drug Delivery Devices Market The Asian Drug Delivery Devices Market was valued at $28 billion in 2013 and expected to be $50 billion by 2018, growing at a CAGR of 12.6%. The report “Asian Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in this market and extensively covered in this report are 3M Company, Alkermes, Baxter International, Inc., Becton, Dickinson & Co., The Dow Chemical Company, Johnson & Johnson, Nektar Therapeutics, SkyePharma PLC,. |
Upcoming |
